GHK-Cu.
Copper tripeptide — extracellular matrix remodelling and skin regeneration.
Build your bag, then either book a consultation (an EU-licensed physician reviews your file — anything declined is refunded) or upload an existing Rx at checkout.
- ✓Magistral preparation — Directive 2001/83/EC Art. 5(1).
- ✓Patient-named prescription only — dispensed against a valid Rx.
- ✓EU-GMP Annex 1 Grade A/B cleanroom compounding.
- ✓Cold-chain shipping across EU/EEA — 2–5 working days.
About GHK-Cu.
GHK-Cu is the copper complex of the tripeptide glycyl-L-histidyl-L-lysine, a fragment of human collagen α-2(I). Plasma levels decline with age; supplementation has been studied for wound healing, skin remodelling and hair-follicle regeneration.
GHK-Cu is well represented in dermatological research and is the active ingredient in several licensed cosmeceutical products. Magistral injection enables targeted delivery for tissue-remodelling protocols.
GHK-Cu modulates gene expression of over 4,000 human genes, with marked effects on extracellular-matrix remodelling: it upregulates collagen and glycosaminoglycan synthesis, increases SOD2 expression and downregulates fibrotic and inflammatory pathways.
Subcutaneous injection or local administration. Doses 1–3 mg per session, 2–3 sessions per week depending on protocol.
Your physician sets the prescription. This is descriptive information, not a self-administration guide.
Lyophilised: store at 2–8 °C, protect from light. Once reconstituted: 2–8 °C, use within 30 days. Do not freeze.
- 01Pickart L, et al. — GHK and DNA: resetting the human genome to health. Biomed Res Int · 2014 · doi: 10.1155/2014/151479
- INN / Name
- GHK-Cu
- Form
- Lyophilised vial · subcutaneous injection
- Strength
- 10mg vial
- Manufacturing
- EU-GMP Annex 1 · Grade A/B
- Endotoxins
- European Pharmacopoeia 2.6.14 · LAL assay
- Identity & purity
- HPLC + MS · > 98%
- Cold chain
- Validated 2–8 °C, monitored end-to-end
- Regulatory basis
- Directive 2001/83/EC · Article 5(1)
2–5 working days
EU / EEA cold-chain delivery, 2–8 °C monitored end-to-end with digital temperature log. Tracking link sent on dispatch.
Magistral preparation
Patient-named preparation under Directive 2001/83/EC Article 5(1). Dispensed exclusively against a valid EU prescription.
EU prescription recognition
Prescriptions written in one EU member state are recognised in others under Directive 2011/24/EU on cross-border healthcare.
Within Healing & Recovery.
- Cat. 01
BPC-157
Synthetic pentadecapeptide derived from human gastric juice — broad tissue-repair signalling.
€60.00 - Cat. 01
TB-500 (Thymosin Beta)
Synthetic version of Thymosin β-4 — actin regulation, angiogenesis and cell migration in injured tissue.
€60.00 - Cat. 01
KPV
α-MSH C-terminal tripeptide with strong anti-inflammatory action.
€30.00